Inhibrx Biosciences, Inc.INBXNASDAQ
LOADING
|||
Switch Symbol:
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | -93.88% | +0.00% | +1200.00% | +0.00% |
| Gross Profit Growth | -738.66% | -144.09% | +0.00% | +538.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | -101.33% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | -101.54% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -101.44% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -101.47% | +0.00% |
| Weighted Average Shares Growth | -67.19% | -73.21% | -71.65% | +6.85% | +0.06% |
| Weighted Average Shares Diluted Growth | -67.19% | -73.21% | -71.65% | +4.46% | +0.06% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +240.48% | -46.02% | -92.96% | -30.28% | -25.73% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -40.29% | -41.29% | -15.92% | -17.92% | -20.26% |
| Book Value per Share Growth | +319.78% | +1046.21% | +2779.41% | -70.75% | -79.38% |
| Debt Growth | -99.12% | -96.17% | -49.49% | +4818.89% | +280.82% |
| R&D Expense Growth | +0.46% | -59.23% | -42.01% | -67.08% | -26.87% |
| SG&A Expenses Growth | -1.08% | +113.99% | -38.97% | -93.12% | -32.48% |